Madrigal Pharmaceuticals, Inc. MDGL Debt - Unamortized Discount (Premium) and Issuance Costs, Net
Debt - Unamortized Discount (Premium) and Issuance Costs, Net at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscount.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s debt - unamortized discount (premium) and issuance costs, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s debt - unamortized discount (premium) and issuance costs, net?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported debt - unamortized discount (premium) and issuance costs, net of $9.67M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s debt - unamortized discount (premium) and issuance costs, net changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s debt - unamortized discount (premium) and issuance costs, net increased by 207.3% year-over-year, from $3.15M to $9.67M.